Maladeniya Charini, Darshani Taniya, Samarakoon Sameera R, Fronczek Frank R, Sameera W M C, Perera Inoka C, Perera Theshini
Department of Chemistry, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Colombo, Sri Lanka.
Bioinorg Chem Appl. 2022 Sep 13;2022:7821284. doi: 10.1155/2022/7821284. eCollection 2022.
Platinum-based compounds are actively used in clinical trials as anticancer agents. In this study, two novel platinum complexes, (1 = [PtCl((SOquin)dpa)], 2 = [PtCl((SOazobenz)dpa)]) containing quinoline and azobenzene appended dipicolylamine sulfonamide ligands were synthesized in good yield. The singlet attributable to methylene CH protons of the ligands of C1 and C2 appears as two doublets in H NMR spectra, which confirms the presence of magnetically nonequivalent protons upon coordination to platinum. Structural data of (SOquin)dpa (L1), (SOazobenz)dpa (L2) and PtCl((SOquin)dpa) confirmed the formation of the desired compounds. Time-dependent density functional theory calculations suggested that the excitation of L1 show quin-unit-based excitations (i.e., ligand-centered charge transfer, LC), while C1 shows the metal-ligand-to-ligand charge-transfer (MLLCT) character. L1 displays intense fluorescence from the LC excited state, while C1 gives phosphorescence from the LC state. Mammalian cell toxicity of ligands and complexes was assessed with NCI-H292 nonsmall-cell lung cancer cells. Further, C1 and C2 showed significantly low IC values compared with (SOazobenz)dpa and PtCl((SOquin)dpa). Fluorescence imaging data of both ligands and complexes revealed the potential fluorescence activity of these compounds for biological imaging. All four compounds are promising novel candidates that can be further investigated on their usage as potential anticancer agents and cancer cell imaging agents.
铂基化合物作为抗癌剂正积极用于临床试验。在本研究中,以良好产率合成了两种新型铂配合物,即含有喹啉和偶氮苯连接的二吡啶甲胺磺酰胺配体的(1 = [PtCl((SOquin)dpa)],2 = [PtCl((SOazobenz)dpa)])。归因于C1和C2配体亚甲基CH质子的单重态在1H NMR光谱中表现为两个双峰,这证实了与铂配位后存在磁不等价质子。(SOquin)dpa (L1)、(SOazobenz)dpa (L2)和PtCl((SOquin)dpa)的结构数据证实了所需化合物的形成。含时密度泛函理论计算表明,L1的激发表现出基于喹啉单元的激发(即配体中心电荷转移,LC),而C1表现出金属-配体-配体电荷转移(MLLCT)特征。L1从LC激发态发出强烈荧光,而C1从LC态发出磷光。用NCI-H292非小细胞肺癌细胞评估了配体和配合物的哺乳动物细胞毒性。此外,与(SOazobenz)dpa和PtCl((SOquin)dpa)相比,C1和C2显示出显著低IC值。配体和配合物的荧光成像数据揭示了这些化合物在生物成像方面的潜在荧光活性。所有四种化合物都是有前景的新型候选物,可进一步研究它们作为潜在抗癌剂和癌细胞成像剂的用途。